tiprankstipranks
Trending News
More News >
Global Bio-chem Technology Group Co. Ltd. (HK:0809)
:0809
Advertisement

Global Bio-chem Technology Group Co. Ltd. (0809) AI Stock Analysis

Compare
0 Followers

Top Page

HK:0809

Global Bio-chem Technology Group Co. Ltd.

(0809)

Select Model
Select Model
Select Model
Neutral 44 (OpenAI - 4o)
Rating:44Neutral
Price Target:
HK$0.00
▼(-100.00% Downside)
The overall stock score is primarily influenced by the company's poor financial performance, characterized by negative equity and high leverage. Technical analysis indicates bearish momentum, further weighing down the score. While the valuation suggests potential undervaluation, the financial instability and technical indicators present significant risks.

Global Bio-chem Technology Group Co. Ltd. (0809) vs. iShares MSCI Hong Kong ETF (EWH)

Global Bio-chem Technology Group Co. Ltd. Business Overview & Revenue Model

Company DescriptionGlobal Bio-chem Technology Group Co. Ltd. (0809) is a leading biotechnology company specializing in the production of bio-based products and chemicals. The company primarily operates in the bio-chemicals sector, focusing on the development and manufacturing of biodegradable materials, biofuels, and other bio-based chemicals. Its core products include bio-monomers, bio-plastics, and various bio-chemicals that serve multiple industries, including packaging, automotive, and consumer goods, contributing to a more sustainable future.
How the Company Makes MoneyGlobal Bio-chem Technology Group Co. Ltd. generates revenue through the sale of its bio-based products and chemicals to various industrial sectors. The company has established a diversified revenue model that includes direct sales of its core products, long-term contracts with key customers, and partnerships with other firms in the bio-chemicals and materials industry. Significant revenue streams come from bulk sales of biodegradable plastics and chemicals, which have seen increasing demand due to the global shift towards sustainability. Additionally, collaborations with research institutions and participation in government initiatives for green technology further enhance its revenue potential.

Global Bio-chem Technology Group Co. Ltd. Financial Statement Overview

Summary
The company exhibits major financial instability with negative equity, high leverage, and inconsistent cash flows. Despite recent improvements in revenue and operating cash flow, the company remains at risk due to historical losses and financial distress.
Income Statement
40
Negative
The company shows significant volatility in revenue, with a recent increase from 2022 to 2023, but overall negative EBIT and net income suggest underlying profitability issues. The negative EBIT margin underscores operational challenges, while EBITDA margin turning positive in 2024 reflects some improvement in operating efficiency.
Balance Sheet
20
Very Negative
The company faces severe financial instability with negative stockholders' equity reflecting balance sheet insolvency, and a high debt-to-equity ratio indicating excessive leverage. The negative equity ratio further highlights financial distress, posing considerable risks.
Cash Flow
30
Negative
Cash flow from operations has improved from negative to positive in 2024, indicating better cash management. However, the free cash flow still faces challenges due to historical negative trends, and the operating cash flow to net income ratio is volatile, highlighting cash flow unpredictability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.29B2.00B1.37B12.71M746.55M848.87M
Gross Profit313.85M218.68M43.64M-263.37M48.35M74.10M
EBITDA104.98M16.85M4.69B-469.06M785.63M-1.39B
Net Income772.61M769.60M4.22B-1.44B-400.80M-2.43B
Balance Sheet
Total Assets4.69B4.54B5.21B5.85B6.48B7.60B
Cash, Cash Equivalents and Short-Term Investments221.55M85.47M315.41M41.77M109.13M153.32M
Total Debt3.60B3.69B5.45B8.91B8.44B8.96B
Total Liabilities6.89B6.50B9.25B13.64B13.18B13.62B
Stockholders Equity-2.21B-1.95B-4.04B-7.54B-6.52B-5.86B
Cash Flow
Free Cash Flow64.48M76.04M-94.24M-94.19M-501.02M-43.02M
Operating Cash Flow67.68M76.04M-50.46M-88.01M-475.21M-26.19M
Investing Cash Flow-3.74M-535.00K-14.37M-413.00K392.59M120.09M
Financing Cash Flow29.89M-76.06M112.62M109.75M-48.66M-25.87M

Global Bio-chem Technology Group Co. Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.08
Price Trends
50DMA
0.09
Negative
100DMA
0.09
Negative
200DMA
0.09
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
28.40
Positive
STOCH
16.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0809, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 28.40 is Positive, neither overbought nor oversold. The STOCH value of 16.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0809.

Global Bio-chem Technology Group Co. Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
HK$1.02B8.555.08%10.12%-1.19%-9.05%
68
Neutral
HK$280.00M10.615.48%0.82%5.43%-25.42%
65
Neutral
HK$1.16B2.5710.38%5.10%-6.58%16.23%
64
Neutral
HK$872.23M-36.99-0.99%14.55%-4.42%-157.03%
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
56
Neutral
HK$59.36M-0.45-28.48%56.39%-81.41%
44
Neutral
HK$1.36B0.9442.14%-81.25%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:0809
Global Bio-chem Technology Group Co. Ltd.
0.08
<0.01
14.29%
HK:1767
TS Wonders Holding Limited
0.28
0.07
33.33%
HK:2147
Zhengwei Group Holdings Company Limited
0.05
0.01
25.00%
HK:2317
Vedan International (Holdings) Ltd.
0.67
0.23
52.27%
HK:3838
China Starch Holdings Limited
0.20
0.02
11.11%
HK:0829
Shenguan Holdings (Group) Limited
0.27
0.02
8.00%

Global Bio-chem Technology Group Co. Ltd. Corporate Events

Global Bio-chem Completes Share Issuance and Bond Conversion to Restructure Debt
Oct 2, 2025

Global Bio-chem Technology Group Co. Ltd. has successfully completed the issuance of Consideration Shares under a specific mandate and the conversion of Convertible Bonds. This strategic move, which involved the issuance of over 2.7 billion Consideration Shares and the conversion of bonds into over 5.1 billion shares, allows the company to fully capitalize its Suppliers Debt, making the Target Companies its wholly-owned subsidiaries. This restructuring is expected to enhance the company’s financial stability and operational efficiency.

Global Bio-chem Technology Group Co. Ltd. EGM Resolution Passed
Sep 18, 2025

Global Bio-chem Technology Group Co. Ltd. announced that an ordinary resolution was passed at their Extraordinary General Meeting (EGM), approving the Share Purchase Agreements (SPAs) and related transactions. The resolution included granting a Specific Mandate for the allotment and issuance of Consideration Shares, with unanimous support from shareholders. This decision reflects the company’s strategic direction and could potentially enhance its market position by facilitating new transactions and expansions.

Global Bio-chem Technology Reports Increased Revenue but Sustains Losses in H1 2025
Aug 29, 2025

Global Bio-chem Technology Group Co. Ltd. reported its unaudited consolidated interim results for the six months ending June 30, 2025, showing a revenue increase to HK$1,185,983,000 from HK$898,541,000 in the same period of 2024. Despite the revenue growth, the company faced a total comprehensive loss of HK$251,895,000, attributed to high finance costs and other expenses, impacting its financial performance and indicating challenges in maintaining profitability.

Global Bio-chem Announces Extraordinary General Meeting for Strategic Approvals
Aug 28, 2025

Global Bio-chem Technology Group Co. Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for September 18, 2025, in Hong Kong. The meeting aims to approve resolutions related to the company’s strategic plans, including the allotment and issuance of Consideration Shares under Specific Mandates. This move is expected to impact the company’s operational strategies and potentially influence its market positioning.

Global Bio-chem Announces Delay in Debt Restructuring Circular
Aug 21, 2025

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The circular, initially expected by 22 August 2025, will now be dispatched by 5 September 2025, as additional time is needed to finalize certain information. This delay may impact stakeholders awaiting detailed information on the debt restructuring and share issuance.

Global Bio-chem Technology Schedules Board Meeting for Interim Results
Aug 19, 2025

Global Bio-chem Technology Group Co. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of 2025 and to consider the payment of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential shareholder returns.

Global Bio-chem Secures EPC Contract for Boiler Refurbishment
Jul 31, 2025

Global Bio-chem Technology Group Co. Ltd. announced the successful closure of a public tender for an EPC Contract related to a Boiler Refurbishment Project. The contract, valued at a maximum of RMB129.1 million, was awarded to Northeast Electric and Liaoning Electric as joint bidders. This transaction is classified as a discloseable transaction under the Listing Rules due to its size, requiring notification and announcement. The project involves comprehensive engineering, procurement, and construction tasks, with incentives for early completion, potentially impacting the company’s operational efficiency and market positioning.

Global Bio-chem Technology Delays Circular Dispatch for Debt Restructuring
Jul 31, 2025

Global Bio-chem Technology Group Co. Ltd. has announced a delay in the dispatch of a circular related to its Suppliers Debt Restructuring Arrangement, which involves the issuance of Consideration Shares under a Specific Mandate. The delay is due to the need for additional time to prepare and finalize necessary information, with the new dispatch date set on or before August 22, 2025. This delay may impact the company’s operational timelines and stakeholder expectations, as the circular is crucial for informing shareholders about the upcoming Extraordinary General Meeting and related transactions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025